All In Biotech

Drug Trial Radar · NCT06958536

A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of Brivekimig in Adults With Moderate to Severe Crohn's Disease

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

99

Planned (sponsor's estimate)

Start

Jun 3, 2025

Primary completion

Dec 17, 2026

Study completion Oct 17, 2029

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
May 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 2, randomized, double-blind, 3-arm study for the treatment of Crohn's disease. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Crohn's disease. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.

Conditions

  • Crohn's Disease

Interventions

  • brivekimigDrug

    Route of Administration: Subcutaneous

  • PlaceboDrug

    Route of Administration: Subcutaneous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants who achieve endoscopic response at Week 16Time frame: From Baseline to Week 16

Locations

78 sites in 12 countries. Site status is shown where the registry gives one.

  • Investigational Site Number: 8400026

    Fairhope, Alabama · Recruiting

  • Investigational Site Number: 8400024

    Tucson, Arizona · Recruiting

  • Investigational Site Number: 8400005

    Escondido, California · Recruiting

  • Investigational Site Number: 8400001

    Lancaster, California · Recruiting

  • Investigational Site Number: 8400029

    San Diego, California · Recruiting

  • Investigational Site Number: 8400032

    Colorado Springs, Colorado · Recruiting

  • Investigational Site Number: 8400017

    Kissimmee, Florida · Recruiting

  • Investigational Site Number: 8400015

    Lighthouse PT, Florida · Recruiting

  • Investigational Site Number 8400028

    Miami, Florida · Recruiting

  • Investigational Site Number: 8400012

    Miami, Florida · Recruiting

  • Investigational Site Number: 8400007

    Orlando, Florida · Recruiting

  • Investigational Site Number: 8400011

    Palmetto Bay, Florida · Recruiting

  • Investigational Site Number: 8400019

    Marietta, Georgia · Recruiting

  • Investigational Site Number: 8400025

    Iowa City, Iowa · Recruiting

  • Investigational Site Number: 8400006

    Kansas City, Kansas · Recruiting

  • Investigational Site Number: 8400022

    Boston, Massachusetts · Recruiting

  • Investigational Site Number: 8400008

    Wyoming, Michigan · Recruiting

  • Investigational Site Number: 8400013

    St Louis, Missouri · Recruiting

  • Investigational Site Number: 8400003

    Chapel Hill, North Carolina · Withdrawn

  • Investigational Site Number: 8400009

    Harrisburg, Pennsylvania · Recruiting

  • Investigational Site Number: 8400002

    Fredericksburg, Texas · Recruiting

  • Investigational Site Number: 8400010

    Houston, Texas · Recruiting

  • Investigational Site Number: 8400016

    Ogden, Utah · Recruiting

  • Investigational Site Number: 8400027

    Richmond, Virginia · Withdrawn

  • Investigational Site Number: 0360001

    Footscray, Australia · Recruiting

  • Investigational Site Number: 0360002

    Brisbane, Queensland, Australia · Recruiting

  • Investigational Site Number: 0360004

    Kurralta Park, South Australia, Australia · Recruiting

  • Investigational Site Number: 0560001

    Leuven, Belgium · Recruiting

  • Investigational Site Number: 1560003

    Changsha, China · Recruiting

  • Investigational Site Number: 1560008

    Changsha, China · Recruiting

  • Investigational Site Number: 1560005

    Changzhou, China · Recruiting

  • Investigational Site Number: 1560001

    Guangzhou, China · Recruiting

  • Investigational Site Number: 1560006

    Hangzhou, China · Recruiting

  • Investigational Site Number: 1560004

    Nanchang, China · Recruiting

  • Investigational Site Number: 1560002

    Shanghai, China · Recruiting

  • Investigational Site Number: 1560007

    Shenyang, China · Recruiting

  • Investigational Site Number: 2030003

    Hradec Králové, Czechia · Recruiting

  • Investigational Site Number: 2030005

    Slaný, Czechia · Withdrawn

  • Investigational Site Number: 2030002

    Brno, JM, Czechia · Recruiting

  • Investigational Site Number: 2500001

    Montpellier, France · Recruiting

Showing 40 of 78 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.